gynoxin optima 20 mg/g (2%) krem dopochwowy
recordati industria chimica e farmaceutica s.p.a - fenticonazoli nitras - krem dopochwowy - 20 mg/g (2%)
acc optima hot 600 mg/3 g proszek do sporządzania roztworu doustnego
sandoz gmbh - acetylcysteinum - proszek do sporządzania roztworu doustnego - 600 mg/3 g
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroksysmal - selektywne leki immunosupresyjne - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
uplizna
horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - leki immunosupresyjne - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.
gripex hot intense 1000 mg + 50 mg + 12,2 mg proszek do sporządzania roztworu doustnego w saszetce
us pharmacia sp. z o.o. - paracetamolum + coffeinum + phenylephrini hydrochloridum - proszek do sporządzania roztworu doustnego w saszetce - 1000 mg + 50 mg + 12,2 mg
soliris
alexion europe sas - Экулизумаб - hemoglobinuria, paroksysmal - leki immunosupresyjne - Солирис wskazany dla dorosłych i dzieci w leczeniu:napadowa nocna hemoglobinuria (pnh). dowodów na efekt kliniczny objawia się u pacjentów z hemolizy z kliniczny objaw(y), świadczy o dużej aktywności choroby, niezależnie od historii transfuzji (patrz rozdział 5. nietypowy zespół hemolityczno-mocznicowy (Агус). Солирис jest wskazany u dorosłych w leczeniu:ogniotrwałe uogólnione z miastenią (ГГМ) u pacjentów z anty-ацетилхолиновому receptora (АЧР) przeciwciała (patrz rozdział 5. zaburzenia neuromyelitis nerwu widma (nmosd) u pacjentów, którzy są anty-akwaporyna-4 (aqp4) przeciwciała z nawracającymi upływem choroby.
acc optima 600 mg tabletki musujące
delfarma sp. z o.o. - tabletki musujące - 600 mg
acc optima 600 mg tabletki musujące
inpharm sp. z o.o. - tabletki musujące - 600 mg
acc optima 600 mg tabletki musujące
forfarm sp. z o.o. - tabletki musujące - 600 mg
acc optima 600 mg tabletki musujące
avrentim sp. z o.o. - tabletki musujące - 600 mg